<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37084750</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-4650</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Lancet. Child &amp; adolescent health</Title><ISOAbbreviation>Lancet Child Adolesc Health</ISOAbbreviation></Journal><ArticleTitle>Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>379</StartPage><EndPage>391</EndPage><MedlinePgn>379-391</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2352-4642(23)00078-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-4642(23)00078-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">To date, more than 761 million confirmed SARS-CoV-2 infections have been recorded globally, and more than half of all children are estimated to be seropositive. Despite high SARS-CoV-2 infection incidences, the rate of severe COVID-19 in children is low. We aimed to assess the safety and efficacy or effectiveness of COVID-19 vaccines approved in the EU for children aged 5-11 years.</AbstractText><AbstractText Label="METHODS">In this systematic review and meta-analysis, we included studies of any design identified through searching the COVID-19 L&#xb7;OVE (living overview of evidence) platform up to Jan 23, 2023. We included studies with participants aged 5-11 years, with any COVID-19 vaccine approved by the European Medicines Agency-ie, mRNA vaccines BNT162b2 (Pfizer-BioNTech), BNT162b2 Bivalent (against original strain and omicron [BA.4 or BA.5]), mRNA-1273 (Moderna), or mRNA-1273.214 (against original strain and omicron BA.1). Efficacy and effectiveness outcomes were SARS-CoV-2 infection (PCR-confirmed or antigen-test confirmed), symptomatic COVID-19, hospital admission due to COVID-19, COVID-19-related mortality, multisystem inflammatory syndrome in children (MIS-C), and long-term effects of COVID-19 (long COVID or post-COVID-19 condition as defined by study investigators or per WHO definition). Safety outcomes of interest were serious adverse events, adverse events of special interest (eg, myocarditis), solicited local and systemic events, and unsolicited adverse events. We assessed risk of bias and rated the certainty of evidence (CoE) using the Grading of Recommendations Assessment, Development and Evaluation approach. This study was prospectively registered with PROSPERO, CRD42022306822.</AbstractText><AbstractText Label="FINDINGS">Of 5272 screened records, we included 51 (1&#xb7;0%) studies (n=17 [33%] in quantitative synthesis). Vaccine effectiveness after two doses against omicron infections was 41&#xb7;6% (95% CI 28&#xb7;1-52&#xb7;6; eight non-randomised studies of interventions [NRSIs]; CoE low), 36&#xb7;2% (21&#xb7;5-48&#xb7;2; six NRSIs; CoE low) against symptomatic COVID-19, 75&#xb7;3% (68&#xb7;0-81&#xb7;0; six NRSIs; CoE moderate) against COVID-19-related hospitalisations, and 78% (48-90, one NRSI; CoE very low) against MIS-C. Vaccine effectiveness against COVID-19-related mortality was not estimable. Crude event rates for deaths in unvaccinated children were less than one case per 100&#x2009;000 children, and no events were reported for vaccinated children (four NRSIs; CoE low). No study on vaccine effectiveness against long-term effects was identified. Vaccine effectiveness after three doses was 55% (50-60; one NRSI; CoE moderate) against omicron infections, and 61% (55-67; one NRSI; CoE moderate) against symptomatic COVID-19. No study reported vaccine efficacy or effectiveness against hospitalisation following a third dose. Safety data suggested no increased risk of serious adverse events (risk ratio [RR] 0&#xb7;83 [95% CI 0&#xb7;21-3&#xb7;33]; two randomised controlled trials; CoE low), with approximately 0&#xb7;23-1&#xb7;2 events per 100&#x2009;000 administered vaccines reported in real-life observations. Evidence on the risk of myocarditis was uncertain (RR 4&#xb7;6 [0&#xb7;1-156&#xb7;1]; one NRSI; CoE low), with 0&#xb7;13-1&#xb7;04 observed events per 100&#x2009;000 administered vaccines. The risk of solicited local reactions was 2&#xb7;07 (1&#xb7;80-2&#xb7;39; two RCTs; CoE moderate) after one dose and 2&#xb7;06 (1&#xb7;70-2&#xb7;49; two RCTs; CoE moderate) after two doses. The risk of solicited systemic reactions was 1&#xb7;09 (1&#xb7;04-1&#xb7;16; two RCTs; CoE moderate) after one dose and 1&#xb7;49 (1&#xb7;34-1&#xb7;65; two RCTs; CoE moderate) after two doses. The risk of unsolicited adverse events after two doses (RR 1&#xb7;21 [1&#xb7;07-1&#xb7;38]; CoE moderate) was higher among mRNA-vaccinated compared with unvaccinated children.</AbstractText><AbstractText Label="INTERPRETATION">In children aged 5-11 years, mRNA vaccines are moderately effective against infections with the omicron variant, but probably protect well against COVID-19 hospitalisations. Vaccines were reactogenic but probably safe. Findings of this systematic review can serve as a basis for public health policy and individual decision making on COVID-19 vaccination in children aged 5-11 years.</AbstractText><AbstractText Label="FUNDING">German Federal Joint Committee.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piechotta</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Immunisation Unit, Robert Koch Institute, Berlin, Germany. Electronic address: piechottav@rki.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siemens</LastName><ForeName>Waldemar</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute for Evidence in Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thielemann</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Immunisation Unit, Robert Koch Institute, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toews</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Evidence in Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Immunisation Unit, Robert Koch Institute, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vygen-Bonnet</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Immunisation Unit, Robert Koch Institute, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kothari</LastName><ForeName>Kavita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Independent consultant, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grummich</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Evidence in Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braun</LastName><ForeName>Cordula</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Evidence in Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapp</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Evidence in Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labont&#xe9;</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Evidence in Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wichmann</LastName><ForeName>Ole</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Immunisation Unit, Robert Koch Institute, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meerpohl</LastName><ForeName>Joerg J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Institute for Evidence in Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harder</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Immunisation Unit, Robert Koch Institute, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Child Adolesc Health</MedlineTA><NlmUniqueID>101712925</NlmUniqueID><ISSNLinking>2352-4642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722752">mRNA-1273.214 COVID-19 vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Child Adolesc Health. 2024 Apr;8(4):e6. doi: 10.1016/S2352-4642(24)00030-0</RefSource><PMID Version="1">38373431</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests WS was employed at Roche from April, 2020, to June, 2021. Roche are not involved and have no influence on this project. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>22</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37084750</ArticleId><ArticleId IdType="pmc">PMC10112865</ArticleId><ArticleId IdType="doi">10.1016/S2352-4642(23)00078-0</ArticleId><ArticleId IdType="pii">S2352-4642(23)00078-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>European Medicines Agency  EMA recommends first COVID-19 vaccine for authorisation in the EU. 2020. https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu</Citation></Reference><Reference><Citation>Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22:1293&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert Koch Institut  W&#xf6;chentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19), 12.01.2023&#x2014;Aktualisierter Stand f&#xfc;r Deutschland. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenberichte_Tab.html</Citation></Reference><Reference><Citation>Naeimi R, Sepidarkish M, Mollalo A, et al. SARS-CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis. EClinicalMedicine. 2023;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9795163</ArticleId><ArticleId IdType="pubmed">36590788</ArticleId></ArticleIdList></Reference><Reference><Citation>Statista  Anzahl der Kinder und Jugendlichen (0- bis 17-J&#xe4;hrige) weltweit nach Altersgruppen im Jahr 2022. https://de.statista.com/statistik/daten/studie/1020443/umfrage/anzahl-der-kinder-und-jugendlichen-weltweit-nach-altersgruppen/</Citation></Reference><Reference><Citation>European Medicines Agency  Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11. 2021. https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11</Citation></Reference><Reference><Citation>Martin B, DeWitt PE, Russell S, et al. Characteristics, outcomes, and severity risk factors associated with SARS-CoV-2 infection among children in the US National COVID Cohort Collaborative. JAMA Netw Open. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826172</ArticleId><ArticleId IdType="pubmed">35133437</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es D, Pissarra R, Reis-Melo A, Guimar&#xe3;es H. Multisystem inflammatory syndrome in children (MISC): a systematic review. Int J Clin Pract. 2021;75</Citation><ArticleIdList><ArticleId IdType="pubmed">34105843</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Dargham SR, Loka S, et al. Coronavirus disease 2019 disease severity in children infected with the omicron variant. Clin Infect Dis. 2022;75:e361&#x2013;e367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047187</ArticleId><ArticleId IdType="pubmed">35404391</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsche Gesellschaft f&#xfc;r P&#xe4;diatrische Infektiologie e. V.  PIMS-Survey-Update: 2022, Kalenderwoche 30. 2022. https://dgpi.de/pims-survey-update/</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark J, Glasziou P, Del Mar C, Bannach-Brown A, Stehlik P, Scott AM. A full systematic review was completed in 2 weeks using automation tools: a case study. J Clin Epidemiol. 2020;121:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">32004673</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . World Health Organization; Oct 6, 2021. A clinical case definition of post COVID-19 condition by a Delphi consensus.https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Hern&#xe1;n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Totten AM, Cheney TP, O'Neil ME, et al. Agency for Healthcare Research and Quality (US); Rockville, MD: 2018. Physiologic Predictors of Severe Injury: Systematic Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">30748156</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann H, Bro&#x17c;ek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. 2013. https://www.guidelinedevelopment.org/handbook</Citation></Reference><Reference><Citation>Sch&#xfc;nemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6692166</ArticleId><ArticleId IdType="pubmed">29432858</ArticleId></ArticleIdList></Reference><Reference><Citation>Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. 2019;10:83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">30067315</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung J, Knapp G. On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat Med. 2001;20:1771&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pubmed">11406840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001;20:3875&#x2013;3889.</Citation><ArticleIdList><ArticleId IdType="pubmed">11782040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson D, Law M, R&#xfc;cker G, Schwarzer G. The Hartung-Knapp modification for random-effects meta-analysis: a useful refinement but are there any residual concerns? Stat Med. 2017;36:3923&#x2013;3934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5628734</ArticleId><ArticleId IdType="pubmed">28748567</ArticleId></ArticleIdList></Reference><Reference><Citation>Balduzzi S, R&#xfc;cker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10231495</ArticleId><ArticleId IdType="pubmed">31563865</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA-1273 COVID-19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022;386:2011&#x2013;2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127699</ArticleId><ArticleId IdType="pubmed">35544369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch YC, St Denis KJ, Kaplonek P, et al. SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children. Sci Transl Med. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348753</ArticleId><ArticleId IdType="pubmed">35881018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiuzzi C, Lippi G. Real-world effectiveness of COVID-19 vaccination among children in Italy. Int J Infect Dis. 2022;122:70&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9119716</ArticleId><ArticleId IdType="pubmed">35598738</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons AE, Amoako A, Grima A, Murison K, Tuite A, Fisman D. Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases in Ontario, Canada. medRxiv. 2022 doi: 10.1101/2022.03.24.22272919. published online Sept 2. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.24.22272919</ArticleId><ArticleId IdType="pmc">PMC10065234</ArticleId><ArticleId IdType="pubmed">37000810</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D, Rosa Duque JS, Yip KM, So HK, Wong WHS, Lau YL. Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong. Commun Med. 2023;3:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9813885</ArticleId><ArticleId IdType="pubmed">36604522</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa Duque JS, Leung D, Yip KM, et al. Effectiveness of BNT162b2 and CoronaVac against pediatric COVID-19-associated hospitalization and moderate-to-severe disease. medRxiv. 2022 doi: 10.1101/2022.09.09.22279426. published online Sept 9. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.09.22279426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood N, Lopez LK, Glover C, et al. Active safety surveillance of COVID-19 mRNA vaccines in children aged 5-15 years in Australia. medRxiv. 2022 doi: 10.1101/2022.07.19.22277827. published online July 22. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.07.19.22277827</ArticleId><ArticleId IdType="pmc">PMC9854254</ArticleId><ArticleId IdType="pubmed">36694479</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan FL, Nguyen JL, Singh TG, et al. Estimated BNT162b2 vaccine effectiveness against infection with delta and omicron variants among US children 5 to 11 years of age. JAMA Network Open. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856252</ArticleId><ArticleId IdType="pubmed">36515946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM, Baggs J, Marquez P, et al. Safety monitoring of Pfizer-BioNTech COVID-19 vaccine booster doses among children aged 5-11 years&#x2014;United States, May 17&#x2013;July 31, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1047&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400528</ArticleId><ArticleId IdType="pubmed">35980875</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D, Chan EY-h, Mu X, et al. Humoral and cellular immunogenicity and safety of 3 doses of CoronaVac and BNT162b2 in young children and adolescents with kidney diseases. medRxiv. 2022 doi: 10.1101/2022.09.14.22279916. published online Sept 15. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.14.22279916</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus W, Urdaneta V, Esposito DB, et al. Analysis of myocarditis among 252 million mRNA-1273 recipients worldwide. Clin Infect Dis. 2023;76:e544&#x2013;e552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384217</ArticleId><ArticleId IdType="pubmed">35666513</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntronwong N, Vichaiwattana P, Klinfueng S, et al. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during pre- and omicron-dominant wave, from January 2021 through November 2022, Thailand: longitudinal study. medRxiv. 2022 doi: 10.1101/2022.12.01.22283006. published online Dec 5. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.12.01.22283006</ArticleId><ArticleId IdType="pmc">PMC10138857</ArticleId><ArticleId IdType="pubmed">37104299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastl AJ, Weaver KN, Zhang X, et al. Humoral immune response and safety of SARS-CoV-2 vaccination in pediatric inflammatory bowel disease. Am J Gastroenterol. 2023;118:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">36114773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu M, Wong HL, Feng Y, et al. Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children aged 5&#x2013;17 years. medRxiv. 2022 doi: 10.1101/2022.10.28.22281532. published online Oct 30. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.28.22281532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM, Marquez P, Zhang B, et al. Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among children aged 5&#x2013;11 years&#x2014;United States, October 12&#x2013;January 1, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9869731</ArticleId><ArticleId IdType="pubmed">36634021</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant. medRxiv. 2022 doi: 10.1101/2022.02.25.22271454. published online Feb 28. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.25.22271454</ArticleId><ArticleId IdType="pmc">PMC9107062</ArticleId><ArticleId IdType="pubmed">35559959</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi DS, Whitaker M, Marks KJ, et al. Hospitalizations of children aged 5&#x2013;11 years with laboratory-confirmed COVID-19&#x2014;COVID-NET, 14 States, March 2020&#x2013;February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:574&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9042359</ArticleId><ArticleId IdType="pubmed">35446827</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir O, Goldberg Y, Mandel M, et al. Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study. Lancet Infect Dis. 2023;23:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9462831</ArticleId><ArticleId IdType="pubmed">36096146</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, AlMukdad S, Ayoub HH, et al. COVID-19 vaccine protection among children and adolescents in Qatar. N Engl J Med. 2022;387:1865&#x2013;1876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9644642</ArticleId><ArticleId IdType="pubmed">36322837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocchio S, Zabeo F, Tremolada G, et al. COVID-19 vaccine effectiveness against omicron variant among underage subjects: the Veneto region's experience. Vaccines. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9413750</ArticleId><ArticleId IdType="pubmed">36016248</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 Vaccine effectiveness against omicron in children 5 to 11 years of age. N Engl J Med. 2022;387:227&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258754</ArticleId><ArticleId IdType="pubmed">35767475</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5&#x2013;11 years and adolescents aged 12&#x2013;15 years&#x2014;PROTECT Cohort, July 2021&#x2013;February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:422&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942308</ArticleId><ArticleId IdType="pubmed">35298453</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang EJ, Choe YJ, Kim RK, Park Y-J. BNT162b2 vaccine effectiveness against the SARS-CoV-2 omicron variant in children aged 5&#x2013;11 years. JAMA Pediatr. 2023;177:319&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857797</ArticleId><ArticleId IdType="pubmed">36622683</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming-Dutra KE, Britton A, Shang N, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance. JAMA. 2022;327:2210&#x2013;2219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107063</ArticleId><ArticleId IdType="pubmed">35560036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco C, Del Manso M, Mateo-Urdiales A, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5&#x2013;11 years in Italy: a retrospective analysis of January-April, 2022. Lancet. 2022;400:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246475</ArticleId><ArticleId IdType="pubmed">35780801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S, Cook AR, Heng D, Ong B, Lye DC, Tan KB. Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years. SSRN. 2022 doi: 10.2139/ssrn.4052133. published online March 28. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4052133</ArticleId><ArticleId IdType="pmc">PMC9342421</ArticleId><ArticleId IdType="pubmed">35857701</ArticleId></ArticleIdList></Reference><Reference><Citation>Pich&#xe9;-Renaud PP, Swayze S, Buchan S, et al. Vaccine effectiveness of BNT162b2 against omicron in children aged 5&#x2013;11 years: a test-negative design. SSRN. 2022 doi: 10.2139/ssrn.4176388. published online Aug 1. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4176388</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5&#x2013;17 years&#x2014;VISION Network, 10 States, April 2021&#x2013;January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:352&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893336</ArticleId><ArticleId IdType="pubmed">35239634</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the omicron variant in children and adolescents. N Engl J Med. 2022;386:1899&#x2013;1909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006785</ArticleId><ArticleId IdType="pubmed">35353976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano LD, Newhams MM, Olson SM, et al. BNT162b2 mRNA vaccination against COVID-19 is associated with decreased likelihood of multisystem inflammatory syndrome in US children Ages 5&#x2013;18 Years. Clin Infect Dis. 2022;76:e90&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384630</ArticleId><ArticleId IdType="pubmed">35924406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM, Shay DK, Klein NP, et al. Safety of COVID-19 vaccination in United States children ages 5 to 11 years. Pediatrics. 2022;150</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9706403</ArticleId><ArticleId IdType="pubmed">35581698</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U, Holm M, Dungu KHS, et al. Risk of myopericarditis after COVID-19 vaccination in Danish children aged 5 to 11 years. Pediatrics. 2022;150</Citation><ArticleIdList><ArticleId IdType="pubmed">35585684</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;lper-Schiek W, Piechotta V, Pilic A, et al. Facing the omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Front Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449804</ArticleId><ArticleId IdType="pubmed">36091023</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liang H, Ding X, Cao Y, Yang D, Duan Y. Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron variant: a systematic review and meta-analysis. J Infect. 2023;86:e64&#x2013;e66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9815878</ArticleId><ArticleId IdType="pubmed">36621642</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JM, Carter MJ, Cheung CR, Ladhani S. Lower risk of multisystem inflammatory syndrome in children with the delta and omicron variants of severe acute respiratory syndrome coronavirus 2. Clin Infect Dis. 2023;76:e518&#x2013;e521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278259</ArticleId><ArticleId IdType="pubmed">35788276</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul-Ehrlich-Institut  Sicherheitsbericht. Bundesinstitut f&#xfc;r Impfstoffe und biomedizinische Arzneimittel. 2022. https://www.pei.de/DE/newsroom/dossier/coronavirus/arzneimittelsicherheit.html</Citation></Reference><Reference><Citation>Public Health Agency of Canada  Canadian COVID-19 vaccination safety report. February 11, 2022. https://health-infobase.canada.ca/covid-19/vaccine-safety/</Citation></Reference><Reference><Citation>Li X, Lai FTT, Chua GT, et al. Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong. JAMA Pediatr. 2022;176:612&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9171561</ArticleId><ArticleId IdType="pubmed">35212709</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Gaudet L, Wingert A, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following COVID-19 vaccination: living evidence syntheses and review. BMJ. 2022;378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9277081</ArticleId><ArticleId IdType="pubmed">35830976</ArticleId></ArticleIdList></Reference><Reference><Citation>Akobeng AK. Understanding randomised controlled trials. Arch Dis Child. 2005;90:840&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1720509</ArticleId><ArticleId IdType="pubmed">16040885</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier BF, Rose AH, Burdinski A, et al. Estimating the distribution of COVID-19-susceptible, -recovered, and -vaccinated individuals in Germany up to April 2022. medRxiv. 2022 doi: 10.1101/2022.04.19.22274030. published online April 23. (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.19.22274030</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and vaccination on symptomatic omicron infections. N Engl J Med. 2022;387:21&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022;386:2201&#x2013;2212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>